Patients treated for diabetic macular edema who were switched from aflibercept to ranibizumab experienced a transient increase in central foveal thickness.
“Eyes with DME switched from aflibercept to ranibizumab therapy demonstrate a transient increase in central foveal thickness at the first visit immediately post-switch. There were no significant changes in visual acuity on short-term follow-up,” study co-author Michael A. Klufas, MD, told Healio/OSN.
One hundred two eyes of 72 patients were included in the retrospective cohort study. All eyes received Eylea (aflibercept,
Uncategorized